Sensitivity was defined as the ability of the MASO-PCR assay to detect FGFR3 mutations (+) and specificity as the ability of assay to identify the absence of FGFR3 mutations (−) in primary NMIBC tumor (diagnosis) as well as recurrence (follow-up). The gene discussed is FGFR3; the disease is neoplasm.